Physician profile
Minesh Patel
NPI 1033409073
$11,343.08
in general payments reported to CMS, 2019-2025
26 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $956 · 2021: $1,480 · 2022: $1,309 · 2023: $1,975 · 2024: $3,016 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,941 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,941.21 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.80 | 2021-2025 | |
| Corium, LLC | $1,340.85 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,288.09 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $855.28 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $813.87 | 2019-2022 | |
| Abbott Laboratories | $772.16 | 2021-2025 | Proclaim, Eterna |
| Neurocrine Biosciences, INC. | $588.65 | 2022-2025 | Ingrezza |
| Tris Pharma INC | $449.45 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $447.45 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $416.47 | 2020-2021 | |
| Allergan, INC. | $375.31 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $241.47 | 2021-2022 | |
| Axsome Therapeutics, INC. | $238.35 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $203.27 | 2023-2025 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $187.09 | 2019-2023 | Spravato |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $112.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $96.23 | 2019-2023 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $91.08 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $90.23 | 2019-2021 | |
| Adlon Therapeutics L.P. | $87.23 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $60.85 | 2024-2025 | Relexxii |
| Alkermes, INC. | $48.43 | 2022-2024 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $33.77 | 2022 | |
| Almatica Pharma LLC | $23.35 | 2023 | Loreev Xr, Sertraline Hcl |
| Avion Pharmaceuticals | $22.93 | 2023 | Methylphenidate Hydrochloride |
| Indivior INC. | $18.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.